These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 27178808)
1. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo. Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808 [TBL] [Abstract][Full Text] [Related]
2. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer. Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619 [TBL] [Abstract][Full Text] [Related]
3. Selective staining and eradication of cancer cells by protein-carrying DARPin-functionalized liposomes. Deyev S; Proshkina G; Baryshnikova O; Ryabova A; Avishai G; Katrivas L; Giannini C; Levi-Kalisman Y; Kotlyar A Eur J Pharm Biopharm; 2018 Sep; 130():296-305. PubMed ID: 29959035 [TBL] [Abstract][Full Text] [Related]
4. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824 [TBL] [Abstract][Full Text] [Related]
5. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Epel M; Carmi I; Soueid-Baumgarten S; Oh S; Bera T; Pastan I; Berzofsky J; Reiter Y Eur J Immunol; 2008 Jun; 38(6):1706-20. PubMed ID: 18446790 [TBL] [Abstract][Full Text] [Related]
6. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Zielinski R; Lyakhov I; Hassan M; Kuban M; Shafer-Weaver K; Gandjbakhche A; Capala J Clin Cancer Res; 2011 Aug; 17(15):5071-81. PubMed ID: 21791637 [TBL] [Abstract][Full Text] [Related]
7. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model. Sokolova EA; Shilova ON; Kiseleva DV; Schulga AA; Balalaeva IV; Deyev SM Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096563 [TBL] [Abstract][Full Text] [Related]
8. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A. Liu H; Lindbo S; Ding H; Altai M; Garousi J; Orlova A; Tolmachev V; Hober S; Gräslund T Int J Oncol; 2019 Jul; 55(1):309-319. PubMed ID: 31180549 [TBL] [Abstract][Full Text] [Related]
9. [Bifunctional Toxin DARP-LoPE Based on the HER2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics]. Proshkina GM; Kiseleva DV; Shilova ON; Ryabova AV; Shramova EI; Stremovskiy OA; Deyev SM Mol Biol (Mosk); 2017; 51(6):997-1007. PubMed ID: 29271963 [TBL] [Abstract][Full Text] [Related]
10. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. Friedman PN; Chace DF; Trail PA; Siegall CB J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873 [TBL] [Abstract][Full Text] [Related]
12. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity. Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207 [TBL] [Abstract][Full Text] [Related]
13. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis. Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492 [TBL] [Abstract][Full Text] [Related]
15. Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis. Nagai T; Tanaka M; Hasui K; Shirahama H; Kitajima S; Yonezawa S; Xu B; Matsuyama T Clin Exp Immunol; 2010 Aug; 161(2):348-56. PubMed ID: 20550546 [TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4697-701. PubMed ID: 2352944 [TBL] [Abstract][Full Text] [Related]
17. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer. Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852 [TBL] [Abstract][Full Text] [Related]
18. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer. Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. Kunwar S; Pai LH; Pastan I J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018 [TBL] [Abstract][Full Text] [Related]
20. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]